The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Construction
  • Business
  • Entertainment
  • Marketing
  • Event

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • Woodforest Acceptance Solutions and AlpacaBOSS Launch Partnership
  • Val Market is the New Frontier of the Online Marketplace
  • 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • Fig Lehigh Valley Celebrates 50th Edition With Summer Launch Party at the Americus Hotel
  • Make America French Again Launches National Campaign
  • RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
  • New Children's Book Teaches Kids the Lesson Its Author Spent a Career Learning: Your Worth Doesn't Need Permission

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • OneVizion Names AI Leader Matthew Kirk as Chief Operating Officer to Drive Governed AI Across Telecom and Electric Utilities
  • Dentists launch independent platform to help practices choose the right technology
  • Contracting Resources Group Recognized by The Daily Record as a 2026 In the Lead: Best Women-Owned Businesses Honoree
  • Woodforest Acceptance Solutions and AlpacaBOSS Launch Partnership
  • New "Lakeside Picnic Ride" Package in Japan's Lake Chuzenji region of Nikko: July 1- November 30, 2026
  • Former MP Shri GV Harsha Kumar Meets AICC President Mallikarjun Kharge
  • Two Attorneys at The Stanley Law Group Named to 2026 South Carolina Super Lawyers List
  • IGH Naturals Announces Peer-Reviewed HuMOLYTE® Study Published in Frontiers in Nutrition
  • LINC to Host CEO Breakfast Forum on July 22
  • The Explorer Shaped Guitar Still a Symbol of Heavy Music with New Releases
  • Allstream Energy Partners Expands AI-Optimized Website Development Division to Meet Growing Demand in GEO / AEO Services
  • Nola Blue announces 'Jumpin' Rockin Rhythm,' the autobiography of Duke Robillard
  • America's Workforce Solution Named an OpenAI SMB Channel Partner, Bringing Enterprise-Grade AI to Main Street
  • Data Tiles Introduces the Decision-Driven Enterprise to North America
  • Disruptor Creations Pioneers New MicroAdventure Series with TravelSpike
  • Hawk Hill Pictures Brings Ukrainian-Language War Drama BUCHA to North American Audiences
  • eCopier Solutions Surpasses 3,000 Five-Star Google Reviews and Maintains Perfect Five-Star Rating
  • Creative Investment Research Welcomes Supreme Court Decision Protecting Federal Reserve Independence While Calling for Continued Accountability
  • Rebecca Francis Team Ranks Among Top 1.5% of Teams and Agents Nationwide
  • Ascent Solar Technologies (N A S D A Q: ASTI): Positioned at the Intersection of the New Space Economy, Defense Innovation and Next-Generation Energy

Popular on PennZone

  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs - 234
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • Greensburg Pennsylvania Martial Arts School Racks Up BJJ Wins
  • A Foundational Claim in Human Secrecy Goes Public
  • Fourth Annual Free Training Day Mid-Atlantic Returns Sept. 19, 2026
  • Dave's Auto Services Sponsors Night of Racing at Action Track USA in Kutztown PA
  • NRE Health Institute Launches International Study Examining Motivations Behind Non-Sexual Nudity
  • ReviewsAlly Launches Evidence-Based Review Platform for VPNs, Business Software, and Online Services
  • New Luxury Single Family Homes From $976,990 in Manalapan
  • Bergey's Truck Centers Recognized in 2026 MACH Alliance Composable Impact Awards

Similar on PennZone

  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
  • Philadelphia Scientist Roohid Parast Advances IBD Research at Johnson & Johnson
  • Medical Experts Highlight the Importance of Second Opinions in Death Investigations
  • NRx Pharmaceuticals (N A S D A Q: NRXP) Accelerates Into National Spotlight as Manufacturing Launch, Federal Policy & AI-Driven Breakthroughs Converge
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us